CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议

2020-06-11 MedSci原创 MedSci原创

Janice

医生/ 主治医师

瑞士制药巨头罗氏公司已与苏州信达生物达成协议，共同开发针对血液瘤和实体癌的通用CAR-T细胞疗法和2:1 T细胞双特异性抗体。

瑞士制药巨头罗氏公司已与信达生物（Innovent Biologics）达成协议，共同开发针对血液瘤和实体癌的通用CAR-T细胞疗法和2:1 T细胞双特异性抗体（包含3个可与抗原结合的结构域：1个与T细胞抗原结合，2个与肿瘤抗原结合）。

罗氏的2:1 T细胞双特异性抗体（图片来源：罗氏）

根据该协议的条款，总部位于中国苏州的信达生物将支付使用罗氏技术的前期费用以及开发、商业里程碑付款和特许权使用费。

如果所有产品均已成功开发并商业化，罗氏将向Innovent支付高达1.4亿美元，再加上高达19.6亿美元的额外开发、批准和销售里程碑付款。罗氏还将为选择开发和商业化的每种产品支付两位数的专利使用费。

Innovent董事长兼首席执行官俞德超表示：“几年前，Innovent首次进入细胞疗法领域，通过与罗氏的合作，我们将迈出更大胆的一步，将基于罗氏新颖的通用CAR-T细胞技术来增强我们的细胞疗法平台，并继续利用罗氏的2：1 T细胞双特异性抗体平台开发和商业化新的双特异性分子。”

2015年，Innovent与礼来公司签署了一项协议，共同开发至少三种实验性抗癌药物，从而在中国开发并最终批准了其癌症免疫疗法抗PD-L1单抗Tyvyt（sintilimab）。

Tyvyt于2018年12月获得中国国家药品监督管理总局批准用于治疗复发和难治性经典霍奇金淋巴瘤（cHL）。

原始出处：

http://www.pmlive.com/pharma_news/roche,_innovent_sign_$2bn_bispecifics_deal_1341997

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
2021-05-17 jinweidong

#特异性#

77 0
[GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
2021-03-23 仁者大医

#CAR-#

81 0
[GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
2020-06-14 研发小兵

双特异性抗体是热点，但是也不一定都有效！

93 0
[GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
2020-06-13 changjitao2009

#Car-T细胞疗法#

124 0
[GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
2020-06-13 yytms

#信达生物#

93 0
[GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
2020-06-13 heli0118

#T细胞疗法#

78 0
[GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
2020-06-13 hyf032

#特异性抗体#

56 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议

相关资讯

科室

工具

服务